M.J. Biopharm insulin glargine
Insulin glargine biosimilar developed by M.J. Biopharm. Reference product Lantus.
About M.J. Biopharm insulin glargine
M.J. Biopharm received its Indian manufacturing permission for insulin glargine in 2024, in vials and cartridges, alongside a permission for the drug substance. It is a specialist Indian insulin maker.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India
Central Drugs Standard Control OrganisationApprovedUnited Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where M.J. Biopharm insulin glargine holds an approval, these are the other insulin glargine biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| CDSCO | 9 | Biocon Biologics (Semglee), Cipla (Cipla insulin glargine), Eli Lilly (Rezvoglar / Abasaglar), Eris Lifesciences (Eris insulin glargine), Genesys Biologics (Genesys insulin glargine), LG Chem (LG Life Sciences insulin glargine), Lupin (Lupin insulin glargine), Regenix (Regenix insulin glargine), Wockhardt (Wockhardt insulin glargine) |
Same developer, other molecules
Other biosimilars in the Atlas developed by M.J. Biopharm: M.J. Biopharm human insulin.
Chronology
- CDSCOMar 2024CDSCO permission granted
Sources
Planning insulin glargine biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant